Alchemab Therapeutics Ltd

Company Name	Alchemab Therapeutics Ltd
Company Status	Active
Company Number	12156844
Category	Private Limited Company
Incorporation Date	14 August 2019(4 years, 8 months ago)

Business Activity

Section M	Professional, scientific and technical activities
SIC 72110	Research and experimental development on biotechnology

Directors

Director Name	John Hamer
Date of Birth	December 1957 (Born 66 years ago)
Nationality	American
Status	Current
Appointed	13 April 2021(1 year, 8 months after company formation)
Appointment Duration	3 years
Role	Managing Partner, Dcvc Bio
Country of Residence	United States
Correspondence Address	East Side Office 1.02 Kings Cross London N1C 4AX

Director Name	Andrew David Levin
Date of Birth	November 1976 (Born 47 years ago)
Nationality	American
Status	Current
Appointed	13 April 2021(1 year, 8 months after company formation)
Appointment Duration	3 years
Role	Managing Director
Country of Residence	United States
Correspondence Address	East Side Office 1.02 Kings Cross London N1C 4AX

Director Name	Prof Houman Ashrafian
Date of Birth	February 1975 (Born 49 years ago)
Nationality	British
Status	Current
Appointed	13 April 2021(1 year, 8 months after company formation)
Appointment Duration	3 years
Role	Managing Partner, Sv Health Managers
Country of Residence	England
Correspondence Address	71 Kingsway London WC2B 6ST

Director Name	Dr Kevin Lee
Date of Birth	April 1968 (Born 56 years ago)
Nationality	British
Status	Current
Appointed	30 June 2021(1 year, 10 months after company formation)
Appointment Duration	2 years, 9 months
Role	CEO
Country of Residence	England
Correspondence Address	East Side Office 1.02 Kings Cross London N1C 4AX

Director Name	Mr Young T. Kwon
Date of Birth	January 1972 (Born 52 years ago)
Nationality	American
Status	Current
Appointed	25 May 2022(2 years, 9 months after company formation)
Appointment Duration	1 year, 11 months
Role	Chief Executive Officer
Country of Residence	United States
Correspondence Address	East Side Office 1.02 Kings Cross London N1C 4AX

Director Name	Mr Jonathon Alan Dines
Date of Birth	August 1982 (Born 41 years ago)
Nationality	British
Status	Resigned
Appointed	14 August 2019(same day as company formation)
Role	Company Director
Country of Residence	United Kingdom
Correspondence Address	71 Kingsway London WC2B 6ST

Director Name	Mr James Allister John Costine
Date of Birth	May 1982 (Born 42 years ago)
Nationality	British
Status	Resigned
Appointed	14 August 2019(same day as company formation)
Role	Company Director
Country of Residence	United Kingdom
Correspondence Address	71 Kingsway London WC2B 6ST

Director Name	Mr Alexander Robert Leech
Date of Birth	October 1972 (Born 51 years ago)
Nationality	British
Status	Resigned
Appointed	14 August 2019(same day as company formation)
Role	Company Director
Country of Residence	United Kingdom
Correspondence Address	71 Kingsway London WC2B 6ST

Director Name	Dr Douglas Treco
Date of Birth	August 1957 (Born 66 years ago)
Nationality	American
Status	Resigned
Appointed	13 April 2021(1 year, 8 months after company formation)
Appointment Duration	1 year (resigned 22 April 2022)
Role	Ceo And President Of Alchemab Therapeutics Ltd
Country of Residence	United States
Correspondence Address	East Side Office 1.02 Kings Cross London N1C 4AX

Location

Registered Address	East Side Office 1.02 Kings Cross London N1C 4AX
Region	London
Constituency	Holborn and St Pancras
County	Greater London
Ward	St Pancras and Somers Town
Built Up Area	Greater London

Accounts

Latest Accounts	31 December 2022 (1 year, 3 months ago)
Next Accounts Due	30 September 2024 (5 months, 1 week from now)
Accounts Category	Group
Accounts Year End	31 December

Returns

Latest Return	28 November 2023 (4 months, 3 weeks ago)
Next Return Due	12 December 2024 (7 months, 3 weeks from now)

Charges

21 May 2021	Delivered on: 27 May 2021 Persons entitled: Silicon Valley Bank Classification: A registered charge Outstanding

Filing History

23 January 2024	Statement of capital following an allotment of shares on 14 January 2024 GBP 5,901.7925 (3 pages)
1 December 2023	Confirmation statement made on 28 November 2023 with updates (7 pages)
17 October 2023	Statement of capital following an allotment of shares on 11 October 2023 GBP 5,901.2925 (3 pages)
11 August 2023	Statement of capital following an allotment of shares on 8 August 2023 GBP 5,899.2056 (3 pages)
8 August 2023	Group of companies' accounts made up to 31 December 2022 (27 pages)
1 August 2023	Termination of appointment of Houman Ashrafian as a director on 26 July 2023 (1 page)
1 August 2023	Appointment of Dame Catherine Elizabeth Bingham as a director on 26 July 2023 (2 pages)
25 April 2023	Statement of capital following an allotment of shares on 20 April 2023 GBP 5,898.163 (3 pages)
27 February 2023	Statement of capital following an allotment of shares on 22 February 2023 GBP 5,897.653 (3 pages)
10 January 2023	Statement of capital following an allotment of shares on 4 January 2023 GBP 4,347.8661 (3 pages)
8 December 2022	Confirmation statement made on 28 November 2022 with updates (6 pages)
3 November 2022	Statement of capital following an allotment of shares on 26 October 2022 GBP 4,344.6161 (3 pages)
30 August 2022	Statement of capital following an allotment of shares on 19 May 2022 GBP 4,341.5309 (3 pages)
30 August 2022	Statement of capital following an allotment of shares on 6 July 2022 GBP 4,344.4536 (3 pages)
15 July 2022	Group of companies' accounts made up to 31 December 2021 (22 pages)
11 July 2022	Statement of capital following an allotment of shares on 14 December 2021 GBP 4,340.1929 (3 pages)
11 July 2022	Second filing of a statement of capital following an allotment of shares on 11 February 2022 GBP 4,340.1929 (4 pages)
1 June 2022	Appointment of Mr. Young T. Kwon as a director on 25 May 2022 (2 pages)
1 June 2022	Termination of appointment of Douglas Treco as a director on 22 April 2022 (1 page)
16 March 2022	Satisfaction of charge 121568440001 in full (1 page)
17 February 2022	Resolutions RES10 ‐ Resolution of allotment of securities (8 pages)
16 February 2022	Statement of capital following an allotment of shares on 11 February 2022 GBP 4,295.1929 ANNOTATION Clarification a second filed SH01 was registered on 11/07/22 (4 pages)
24 January 2022	Confirmation statement made on 28 November 2021 with updates (5 pages)
17 January 2022	Statement of capital following an allotment of shares on 5 August 2021 GBP 2,745.406 (3 pages)
19 October 2021	Registered office address changed from 55-56 Russell Square London WC1B 4HP England to East Side Office 1.02 Kings Cross London N1C 4AX on 19 October 2021 (1 page)
23 July 2021	Accounts for a small company made up to 31 December 2020 (7 pages)
6 July 2021	Appointment of Dr Kevin Lee as a director on 30 June 2021 (2 pages)
27 May 2021	Registration of charge 121568440001, created on 21 May 2021 (6 pages)
11 May 2021	Statement of capital following an allotment of shares on 13 April 2021 GBP 2,677.5176 (3 pages)
10 May 2021	Notification of a person with significant control statement (2 pages)
10 May 2021	Appointment of Houman Ashrafian as a director on 13 April 2021 (2 pages)
10 May 2021	Appointment of Dr Douglas Treco as a director on 13 April 2021 (2 pages)
10 May 2021	Appointment of John Hamer as a director on 13 April 2021 (2 pages)
10 May 2021	Cessation of Sv7 (Imf) Gp Llp as a person with significant control on 13 April 2021 (1 page)
7 May 2021	Appointment of Andrew David Levin as a director on 13 April 2021 (2 pages)
7 May 2021	Termination of appointment of James Allister John Costine as a director on 13 April 2021 (1 page)
7 May 2021	Termination of appointment of Alex Leech as a director on 13 April 2021 (1 page)
5 May 2021	Resolutions RES10 ‐ Resolution of allotment of securities RES01 ‐ Resolution of adoption of Articles of Association (3 pages)
5 May 2021	Memorandum and Articles of Association (56 pages)
30 March 2021	Second filing of Confirmation Statement dated 28 November 2020 (3 pages)
30 March 2021	Second filing of Confirmation Statement dated 28 November 2019 (3 pages)
29 March 2021	Cessation of Dementia Discovery Gp Lp as a person with significant control on 2 April 2020 (1 page)
25 February 2021	Registered office address changed from Burgess Hodgson, Camburgh House 27 New Dover Road Canterbury Kent CT1 3DN England to 55-56 Russell Square London WC1B 4HP on 25 February 2021 (1 page)
24 February 2021	Confirmation statement made on 28 November 2020 with updates (4 pages)
24 February 2021	Confirmation statement made on 28 November 2020 with updates ANNOTATION Clarification a second filed CS01 statement of capital & shareholder information was registered on 30/03/21 (5 pages)
30 June 2020	Statement of capital following an allotment of shares on 2 April 2020 GBP 347.6667 (3 pages)
30 June 2020	Termination of appointment of Jonathon Alan Dines as a director on 9 April 2020 (1 page)
30 June 2020	Registered office address changed from 4th Floor Reading Bridge House George Street Reading Berkshire RG1 8LS United Kingdom to Burgess Hodgson, Camburgh House 27 New Dover Road Canterbury Kent CT1 3DN on 30 June 2020 (1 page)
28 November 2019	Confirmation statement made on 28 November 2019 with updates (4 pages)
28 November 2019	Confirmation statement made on 28 November 2019 with updates ANNOTATION Clarification a second filed CS01 statement of capital & shareholder information was registered on 30/03/21 (5 pages)
4 November 2019	Resolutions RES10 ‐ Resolution of allotment of securities RES11 ‐ Resolution of removal of pre-emption rights RES13 ‐ Sub-division of ordinary issued shares 17/10/2019 (3 pages)
4 November 2019	Sub-division of shares on 17 October 2019 (4 pages)
4 November 2019	Statement of capital following an allotment of shares on 17 October 2019 GBP 2,666,667 (4 pages)
9 September 2019	Current accounting period extended from 31 August 2020 to 31 December 2020 (1 page)
9 September 2019	Change of details for Dementia Discovery Gp Lp as a person with significant control on 14 August 2019 (2 pages)
9 September 2019	Director's details changed for Mr Jon Dines on 14 August 2019 (2 pages)
14 August 2019	Incorporation Statement of capital on 2019-08-14 GBP .02 MODEL ARTICLES ‐ Model articles adopted (13 pages)

Alchemab Therapeutics Ltd

Business Activity

Directors

Location

Accounts

Returns

Charges

Filing History

Contact Companies London